

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10659116
Filing Date	09-10-2003
First Named Inventor	Daniel M. Lafontaine
Title	Cryoplasty Device and Method
Art Unit	3739
Examiner Name	Roy Dean Gibson
Attorney Docket Number	1001.2573104

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

28075

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number.

OR

☐ The address associated with Customer Number:

☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Fax

I am, the:

☐

Applicant/Inventor.

☒

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE OF Applicant or Assignee of Record

Signature	<i>Steven A. McAuley</i>	Date	6/18/10
Name	Steven A. McAuley	Telephone	713.444.2425
Title and Company	Assistant Secretary, Patent Council		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE
REGARDING CERTAIN PATENT MATTERS
EFFECTIVE THROUGH: December 31, 2010**


I, Lawrence J. Knopf, as Senior Vice President and Deputy General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Action Medical, Inc.; Advanced Stent Technologies, Inc.; AFx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); BEI Medical Systems International, Inc.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Neuromodulation Corporation; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; Cardiothoracic Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CryoCor, Inc.; CryoVascular Systems, Inc.; Embolic Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quantum Corporation; Radio Therapeutics Corporation; Remon Medical Technologies, Ltd.; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Poissant Reg. No. 56,871
Alana Bergman Reg. No. 47,420
James R. Chiapetta Reg. No. 39,634
Sara J. Citrowske Reg. No. 55,076
Richard R. Clapp Reg. No. 31,751
Jeffrey P. Cook Reg. No. 48,649
Luke R. Dohmen Reg. No. 36,783
Peter J. Gafner Reg. No. 36,517
Lori J. Heinrichs Reg. No. 43,667

Albert K. Kau Reg. No. 40,672
Philip H. Lee Reg. No. 50,645
Kurt W. Lockwood Reg. No. 40,704
Jeffrey Z. Mann Reg. No. 51,994
Steven A. McAuley Reg. No. 46,084
Todd P. Messal Reg. No. 42,883
Tyler L. Nasiedlak Reg. No. 40,099
William J. Shaw Reg. No. 43,111


Lawrence J. Knopf, Senior Vice President and Deputy General Counsel

7/23/07
Date

COMMONWEALTH OF MASSACHUSETTS)

COUNTY OF MIDDLESEX) ss.

On this 23rd day of July, 2007, before me personally appeared Lawrence J. Knopf to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.


Notary Public

**Nona E Hurd
NOTARY PUBLIC
My commission expires Sept 18, 2009**

[e:\limited\auth07232009]